Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1050 participants.

Also called NCT07324837

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,050 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07324837
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07324837. Randomized; triple masking; primary purpose treatment. Start 2026-06-09 (actual); primary completion 2028-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
Acronym
FRIDA-CT
Condition
Ischemic Stroke, Acute
Intervention (Drug)
non-immunogenic staphylokinase
Intervention (Drug)
Placebo
Lead sponsor
Supergene, LLC (class: industry)

Record details

Record id
cardio:ct-nct07324837
Content hash
71e0dfdcf4755c0d943d9f106d7b199a7c047b871726d86292ba21aa8590e598